Sanofi, a global pharmaceutical company, has developed a next-generation insulin that can help people with diabetes lower their risk of hypoglycemia.

What is Hypoglycemia?

Hypoglycemia is a condition when your blood sugar levels drop too low, usually below 70 mg/dl. It can cause symptoms such as sweating, shakiness, confusion, dizziness, and a rapid heartbeat.

If left untreated, it can lead to unconsciousness, seizures, or even death.

Why Does Hypoglycemia Occur?

Hypoglycemia can occur for a variety of reasons. It can happen when you skip meals, exercise more than usual, take too much insulin or other diabetes medications, or drink alcohol without eating enough food.

In some cases, hypoglycemia can occur without any clear cause.

What is Next-Generation Insulin?

Next-generation insulin is a type of insulin that has been designed to lower the risk of hypoglycemia. It works differently than traditional insulins by closely mimicking the natural release of insulin in the body.

This results in more stable blood sugar levels and fewer episodes of hypoglycemia.

How Does Next-Generation Insulin Work?

Next-generation insulin works by using a modified molecular structure that allows it to mimic the natural release of insulin in the body.

Related Article Improved Blood Sugar Control with Sanofi’s New Insulin

This means that it is released more slowly and steadily compared to traditional insulins, which can cause blood sugar levels to drop too quickly.

What are the Benefits of Next-Generation Insulin?

Next-generation insulin can offer several benefits to people with diabetes:.

• Lower risk of hypoglycemia
• More stable blood sugar levels
• Fewer injections needed per day
• Improved quality of life

What are the Types of Next-Generation Insulin?

Sanofi has developed two types of next-generation insulin:.

• Toujeo (insulin glargine 300 units/mL)
• Admelog (insulin lispro)

Toujeo

Toujeo is a long-acting insulin that is designed to be taken once a day. It uses a proprietary technology called OptiClik that allows for precise dosing and minimal needle exposure.

Admelog

Admelog is a rapid-acting insulin that is designed to be taken before meals. It works faster than traditional insulins, which means it can help prevent spikes in blood sugar levels after meals.

Who Can Benefit from Next-Generation Insulin?

Next-generation insulin can benefit people with diabetes who are at risk of hypoglycemia or who have difficulty managing their blood sugar levels with traditional insulins.

Conclusion

Next-generation insulin is a promising development in diabetes management. It can help lower the risk of hypoglycemia and provide more stable blood sugar levels, which can help improve the quality of life for people with diabetes.